Insurability of HIV-positive people treated with antiretroviral therapy in Europe: collaborative analysis of HIV cohort studies
Josee Kaulich-Bartz, Wayne Dam, Margaret T May, Bruno Lederberger, Urs Widmer, Andrew N Phillips, Sophie Grabar, Amanda Mocroft, Josep Vilaro, Ard van Sighem, Santiago Moreno, François Dabis, Antonella D'Arminio Monforte, Ramon Teira, Suzanne M Ingle, Jonathan A C Sterne, Writing Committee for the Antiretroviral Therapy Cohort Collaboration, Josee Kaulich-Bartz, Wayne Dam, Margaret T May, Bruno Lederberger, Urs Widmer, Andrew N Phillips, Sophie Grabar, Amanda Mocroft, Josep Vilaro, Ard van Sighem, Santiago Moreno, François Dabis, Antonella D'Arminio Monforte, Ramon Teira, Suzanne M Ingle, Jonathan A C Sterne, Writing Committee for the Antiretroviral Therapy Cohort Collaboration
Abstract
Objective: To increase equitable access to life insurance for HIV-positive individuals by identifying subgroups with lower relative mortality.
Design: Collaborative analysis of cohort studies.
Methods: We estimated relative mortality from 6 months after starting antiretroviral therapy (ART), compared with the insured population in each country, among adult patients from European cohorts participating in the ART Cohort Collaboration (ART-CC) who were not infected via injection drug use, had not tested positive for hepatitis C, and started triple ART between 1996-2008. We used Poisson models for mortality, with the expected number of deaths according to age, sex and country specified as offset.
Results: There were 1236 deaths recorded among 34,680 patients followed for 174,906 person-years. Relative mortality was lower in patients with higher CD4 cell count and lower HIV-1 RNA 6 months after starting ART, without prior AIDS, who were older, and who started ART after 2000. Compared with insured HIV-negative lives, estimated relative mortality of patients aged 20-39 from France, Italy, United Kingdom, Spain and Switzerland, who started ART after 2000 had 6-month CD4 cell count at least 350 cells/μl and HIV-1 RNA less than 10⁴ copies/ml and without prior AIDS was 459%. The proportion of exposure time with relative mortality below 300, 400, 500 and 600% was 28, 43, 61 and 64%, respectively, suggesting that more than 50% of patients (those with lower relative mortality) could be insurable.
Conclusion: The continuing long-term effectiveness of ART implies that life insurance with sufficiently long duration to cover a mortgage is feasible for many HIV-positive people successfully treated with ART for more than 6 months.
© 2013 Creative Common License
Figures
References
- Hogg R, Lima V, Sterne JAC, Grabar S, Battegay M, Bonarek M, et al. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies 1. Lancet 2008; 372:293–299
- Willig JH, Abroms S, Westfall AO, Routman J, Adusumilli S, Varshney M, et al. Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy. AIDS 2008; 22:1951–1960
- Hogg RS, Heath KV, Yip B, Craib KJ, O'Shaughnessy MV, Schechter MT, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998; 279:450–454
- Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998; 352:1725–1730
- Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, D’Arminio MA, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362:22–29
- Anglaret X, Toure S, Gourvellec G, Tchehy A, Zio L, Zaho M, et al. Impact of vital status investigation procedures on estimates of survival in cohorts of HIV-infected patients from Sub-Saharan Africa. J Acquir Immune Defic Syndr 2004; 35:320–323
- Zwahlen M, Harris RJ, Hogg R, Costagliola D, May M, de WF, et al. Mortality of HIV-infected patients starting potent antiretroviral therapy: Comparison with the general population in eight industrialized countries. Int J Epidemiol 2009; 38:1624–1633
- Chene G, Sterne JA, May M, Costagliola D, Ledergerber B, Phillips AN, et al. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet 2003; 362:679–686
- Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360:119–129
- May MT, Ingle SM, Costagliola D, Justice AC, de Wolf F, Cavassini M, et al. Cohort profile: Antiretroviral Therapy Cohort Collaboration (ART-CC). IJE. 2013 doi: 10.1093/ije/dyt010. (in press)
- McCullagh P, Nelder J. Generalized linear models: Chapman and Hall; 1989
- Dickman PW, Sloggett A, Hills M, Hakulinen T. Regression models for relative survival. Stat Med 2004; 23:51–64
- Akaike H. A new look at the statistical model identification. IEEE Trans Autom Control AC 1974; 19:716–723
- Lewden C, Bouteloup V, De Wit S, Sabin C, Mocroft A, Wasmuth JC, et al. All-cause mortality in treated HIV-infected adults with CD4 ≥ 500 cells/mm3 compared with the general population: evidence from a large European observational cohort collaboration. Int J Epidemiol 2012; 41:433–445
- van Sighem AI, Gras LA, Reiss P, Brinkman K, de Wolf F. Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals. AIDS 2010; 24:1527–1535
- Lohse N, Hansen AB, Pedersen G, Kronborg G, Gerstoft J, Sorensen HT, et al. Survival of persons with and without HIV infection in Denmark, 1995–2005. Ann Intern Med 2007; 146:87–95
- Gill MJ, May M, Lewden C, Saag M, Mugavero MJ, Reiss P, et al. Causes of death in HIV-1 infected patients treated with antiretroviral therapy 1996–2006: collaborative analysis of 13 HIV cohorts. Clin Infect Dis 2010; 50:1387–1396
- Centers for Disease Control and Prevention Establishing a Holistic Framework to Reduce Inequities in HIV, Viral Hepatitis, STDs, and Tuberculosis in the United States 2010. Available from: [Accessed 16 August 2012]
- Denning PH, DiNenno EA, Wiegand RE. Characteristics associated with HIV infection among heterosexuals in urban areas with high AIDS prevalence-24 cities, United States, 2006–2007 (Reprinted from MMWR vol 60, p.1045; 2011). JAMA 2011; 306:1320–1322
- US Department of Health & Human Services How the Affordable Care Act Helps People Living with HIV/AIDS: 2011 and Beyond. Available from: [Accessed 16 August 2012]
- Nakagawa F, Lodwick RK, Smith CJ, Smith R, Cambiano V, Lundgren J, et al. Projected life expectancy of people with HIV according to timing of diagnosis. AIDS 2012; 26:335–343
- Dutch Association of Insurers. Insurability of people with HIV: a step closer 2005:28. [[Accessed 16 August 2012]]; Available from: .
- Dutch Asscoiation of Insurers. HIV Insurability Expanded: Report of the HIV Working Group 2009:38 Available from: [Accessed 16 August 2012]
- AIDS-HILFE SCHWEIZ. Life insurance policies for people living with HIV: International analysis. 2008:7 Available from: [Accessed 16 August 2012]
- Hughes RA, Sterne JA, Walsh J, Bansi L, Gilson R, Orkin C, et al. Long-term trends in CD4 cell counts and impact of viral failure in individuals starting antiretroviral therapy: UK Collaborative HIV Cohort (CHIC) study. HIV Med 2011; 12:583–593
- Lewden C, Chene G, Morlat P, Raffi F, Dupon M, Dellamonica P, et al. HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr 2007; 46:72–77
- Mocroft A, Sterne JA, Egger M, May M, Grabar S, Furrer H, et al. Variable impact on mortality of AIDS-defining events diagnosed during combination antiretroviral therapy: not all AIDS-defining conditions are created equal. Clin Infect Dis 2009; 48:1138–1151
Source: PubMed